Altmetric

Presentation, management and mortality after a first MI in people with and without asthma: a study using UK MINAP data

File Description SizeFormat 
MI_Asthma_submit kr submitted revision clean.docxAccepted version144.17 kBMicrosoft WordView/Open
1479972317702140.pdfPublished version453.24 kBAdobe PDFView/Open
Title: Presentation, management and mortality after a first MI in people with and without asthma: a study using UK MINAP data
Authors: Pinto, P
Rothnie, K
Lui, K
Timmis, A
Smeeth, L
Quint, JK
Item Type: Journal Article
Abstract: Background: Asthma has been associated with a higher incidence of myocardial infarction (MI), higher prevalence of MI risk factors and higher burden of cardiovascular diseases. However, detailed associations between the presentation and initial management at the time of MI and post-MI outcomes in people with asthma compared to the general population have not been studied. Methods: 300,161 people were identified with a first MI over the period 2003-2013 in the Myocardial Ischaemia National Audit Project database (MINAP), of whom 8,922(3%) had asthma. Logistic regression was used to compare presentation, in-hospital care, in-hospital and 180-day post discharge all-cause mortality in people with and without asthma adjusting for demographics and comorbidities, diagnosis on arrival, and secondary prevention. Results: People with asthma were more likely to have a delay in their MI diagnosis following a STEMI (OR 1.38, 1.06;1.79) but not a nSTEMI (OR 1.04, 0.92;1.17) compared to people without asthma, and a delay in reperfusion (OR 1.19,1.09;1.30) following a STEMI. They were much less likely to be discharged on a beta-blocker following a STEMI or nSTEMI (OR 0.24, 0.21;0.28 and OR 0.27, 0.24;0.30, respectively). There was no difference in in-hospital or 180-day mortality (OR 0.98, 0.59;1.62 and OR 0.99, 0.72;1.36) following a STEMI or a nSTEMI (OR 0.89, 0.47;1.68 and OR 1.05; 0.85-1.28). Conclusions: Although people with asthma were more likely to have a delay in diagnosis following a STEMI but not a nSTEMI compared to the general population, were more likely to have a delay in re-perfusion therapy and were much less likely to receive beta-blockers following a STEMI or nSTEMI, there was no difference in the prescriptions of other secondary prevention medications. None of the differences in presentation or management were associated with an increase in all-cause in-hospital or 180-day mortality in people with asthma compared to the general population.
Issue Date: 10-Apr-2017
Date of Acceptance: 23-Feb-2017
URI: http://hdl.handle.net/10044/1/45012
DOI: https://dx.doi.org/10.1177/1479972317702140
ISSN: 1479-9731
Publisher: SAGE Publications (UK and US)
Start Page: 60
End Page: 70
Journal / Book Title: Chronic Respiratory Disease
Volume: 15
Issue: 1
Copyright Statement: This article is distributed under the terms of the Creative Commons Attribution 3.0 License (http://www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Sponsor/Funder: GlaxoSmithKline Services Unlimited
Funder's Grant Number: PO #3000793769
Keywords: Asthma
cardiovascular disease
epidemiology
mortality
myocardial infarction
quality of care
1102 Cardiovascular Medicine And Haematology
1103 Clinical Sciences
Respiratory System
Publication Status: Published
Open Access location: http://journals.sagepub.com/doi/full/10.1177/1479972317702140
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons